OECD Book: Innovation in Pharmaceutical Biotechnology - Comparing National Innovation Systems at the Sectoral Level (link)

Paris, 10 Apr 2006

What are the specific characteristics of innovation in pharmaceutical biotechnology? How do biopharmaceutical innovation systems in OECD countries perform and which policies are suitable to foster performance?

This publication examines the innovation system in pharmaceutical biotechnology in eight OECD countries: Belgium, Finland, France, Germany, Japan, the Netherlands, Norway and Spain. The report summarises the results of in-depth studies, providing a comparative analysis of participating countries' performance in science and innovation in biopharmaceuticals. It highlights specific characteristics of the national biopharmaceutical innovation systems in terms of their international openness and the specific role of demand-side factors in the innovation process. Major systemic failures affecting the functioning of the biopharmaceutical innovation systems are identified. Based on rich evidence, the report draws policy recommendations to foster innovation in biopharmaceuticals advocating an integrated policy approach.

This study forms part of a larger effort to compare innovation processes in different industry sectors and technological fields to provide policy guidance and to more fully elaborate the national innovation systems (NIS) approach to policy making.

Table of contents

Foreword

Executive Summary (English) - available for free download

Note de synthèse (French) - available for free download

  • Chapter 1. Introduction

  • Chapter 2. Summary of Country Studies:
    • Belgium
    • Finland
    • France
    • Germany
    • Japan
    • The Netherlands
    • Norway
    • Spain
Chapter 3. Comparison of Performance in National Biopharmaceutical Innovation Systems

Chapter 4. Openness of the Biopharmaceutical Innovation System

Chapter 5. Comparison of Selected Demand-side Factors

Chapter 6. Structure, Dynamics and Performance in National Biopharmaceutical Innovation Systems

Chapter 7. Systemic Imperfections in Biopharmaceutical Innovation Systems

Chapter 8. Policy Implications

The full volume can be browsed on the OECD Online Bookshop.

Further information

Organisation for Economic Co-operation and Development
http://www.oecd.org
Item source

Already registered?

Sign in now if you are already registered or a current subscriber. Or subscribe for unrestricted access to our digital editions and iPad and iPhone app.

Register to continue  

You've enjoyed reading five THE articles this month. Register now to get five more, or subscribe for unrestricted access.

Most Commented

  • Elly Walton illustration (16 July 2015)

Whether in jest or not, sexist language shows an insensitivity to gender issues at odds with academic values, argues Dorothy Bishop

  • Two men looking surprised in an office

Report says projects fail when scholars obsessed with “shiny things” ignore business needs

  • Tony Little, Eton College headmaster, 2007

Tony Little points to ‘increasing gap’ between teaching standards at sixth form and university

  • AC Grayling, writer and academic

A. C. Grayling’s ‘Oxbridge-style’ private college strikes agreement with post-92 institution